American Cancer Society releases survivorship care guidelines for colorectal cancer survivors
the ONA take:
The American Cancer Society (ACS) has released its second in a series of cancer survivorship care guidelines. These guidelines provide recommendations to primary care clinicians for providing comprehensive care to survivors of colorectal cancer.
The new guidelines offer recommendations for identifying and managing potential physical and psychosocial long-term and late effects of colorectal cancer and its treatment, including screening for recurrence and early detection of second primary cancers.
A multidisciplinary team reviewed relevant literature and publicly available clinical practice guidelines from the United States and around the world to develop the survivorship guidelines in a process that follows the model used to develop screening guidelines. As is done with screening guidelines, ACS will update its survivorship care guidelines every 5 years as new research is available.
New guidelines address long-term needs of colorectal cancer survivors
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|